TrialThe lancet. HIV2022

Once-daily dolutegravir-based antiretroviral therapy in infants and children living with HIV from age 4 weeks: results from the below 14 kg cohort in the randomised ODYSSEY trial.

Pauline Amuge et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.